Pancreatic Neuroendocrine Tumor
📧 Sign up to get email alerts when something new happens for Pancreatic Neuroendocrine Tumor.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-01-13Clinical Trial Update: ATRX/DAXX in EUS-FNB Specimens of Pan-NETs
The trial investigates ATRX/DAXX status in EUS-guided fine-needle biopsy specimens from pancreatic neuroendocrine tumors. It is currently ac…
-
CLINICAL_TRIALS research · 2026-01-09Clinical Trial Update: Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors [Phase 1]
A Phase 1 trial is evaluating the combination of Fulvestrant with Lu-DOTATATE for metastatic pancreatic neuroendocrine tumors; recruitment i…
-
CLINICAL_TRIALS research · 2025-12-23Clinical Trial Update: Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors [Phase 2]
CVM-1118 is being studied in a Phase 2 trial for advanced neuroendocrine tumors. The study is currently active but not recruiting.
-
CLINICAL_TRIALS research · 2025-12-22Clinical Trial Update: Preventing Postoperative Complications in Patients Undergoing High-risk Pancreatoduodenectomy With a Bundle Approach Including Hydrocortisone, Octreotide, and the Teres Ligament Patch (PANENCA) [Phase 4]
Phase 4 clinical trial evaluating a perioperative bundle including hydrocortisone, octreotide, and a teres ligament patch to reduce postoper…
-
CLINICAL_TRIALS research · 2025-12-17Clinical Trial Update: Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors [Phase 4]
This study evaluates whether surgical debulking prior to peptide receptor radionuclide therapy improves outcomes in well-differentiated gast…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-12-15Clinical Trial Update: Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors [Phase 2]
A Phase 2 clinical trial is evaluating chemotherapy after surgical resection for high-risk pancreatic neuroendocrine tumors, with recruitmen…
-
CLINICAL_TRIALS research · 2025-12-10Clinical Trial Update: Superb Microvascular Imaging (SMI) and Two-Dimensional Endoscopic Ultrasound Guided Shear Wave Elastography (2D-SWE-EUS) in Differential Diagnosis of Pancreatic Adenocarcinoma (PA) From Other Pancreatic Solid Lesions (PSLs) and Pancreatic neuroendocrinE Tumors (pNETs) Malignancy [NA]
This clinical trial evaluates Superb Microvascular Imaging and two-dimensional EUS-guided shear wave elastography to differentiate pancreati…
-
CLINICAL_TRIALS research · 2025-12-09Clinical Trial Update: Endoscopic Ultrasound-guided Radiofrequency Ablation for Upper Gastrointestinal Tract Lesions
Clinical trial update on recruiting for a study evaluating endoscopic ultrasound-guided radiofrequency ablation of upper gastrointestinal tr…
-
CLINICAL_TRIALS trial_result · 2025-11-04Clinical Trial Update: A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors [EARLY_Phase 1]
Early-phase safety study of the radiopharmaceutical 212Pb-VMT-alpha-NET in patients with neuroendocrine tumors is active but not currently r…
-
FDA approval · 2025-10-30FDA Approved: EVEROLIMUS — Original Application (Novugen Pharma (USA) LLC.)
FDA approved a generic version of Everolimus from Novugen Pharma (USA) LLC under an Original Application (ANDA).
-
CLINICAL_TRIALS trial_result · 2025-10-20Clinical Trial Update: Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery [Phase 1]
Phase 1 trial update of sapanisertib with ziv-aflibercept in patients with recurrent, metastatic, or unresectable solid tumors, including fi…
-
CLINICAL_TRIALS research · 2025-10-01Clinical Trial Update: Patients With High-grade Pancreatic Neuroendocrine Tumors [Phase 2]
Phase 2 clinical trial update indicating enrollment by invitation for patients with high-grade pancreatic neuroendocrine tumors.
-
CLINICAL_TRIALS research · 2025-09-11Clinical Trial Update: Real-World Effectiveness and Pharmacogenetics of Belzutifan in VHL Syndrome: The BELIEVE-VHL Trial [Phase 2]
Phase 2 BELIEVE-VHL trial is assessing real-world effectiveness and pharmacogenetics of belzutifan in Von Hippel-Lindau syndrome; recruitmen…
-
CLINICAL_TRIALS research · 2025-08-22Clinical Trial Update: Risk Factors, Prognosis, Clinicopathological and Metabolic Characteristics of EO- vs LO-PanNETs
A clinical trial evaluating risk factors, prognosis, clinicopathological features, and metabolic characteristics of early-onset versus late-…
-
CLINICAL_TRIALS trial_result · 2025-06-24Clinical Trial Update: 68-Ga-labeled Octreotide Analogues PET in Duodenal-pancreatic Neuroendocrine Tumours [Phase 2]
Phase 2 clinical trial evaluating 68Ga-labeled octreotide analogue PET imaging in duodenal and pancreatic neuroendocrine tumors. The study s…
-
CLINICAL_TRIALS research · 2025-06-03Clinical Trial Update: Gallium (68Ga) Edotreotide PET/CT for Imaging Patients With Gastrointestinal Pancreatic Neuroendocrine Tumors [Phase 3]
A Phase 3 clinical trial is evaluating Gallium-68 Edotreotide PET/CT imaging for patients with advanced gastroenteropancreatic neuroendocrin…
-
CLINICAL_TRIALS research · 2025-05-25Clinical Trial Update: Pancreatic Radiofrequency Under High Echo-endoscopy in the Management of Pancreatic Neuroendocrine Tumors [NA]
A recruiting study evaluating pancreatic radiofrequency ablation under endoscopic ultrasound guidance for pancreatic neuroendocrine tumors.
-
CLINICAL_TRIALS trial_result · 2025-05-11Clinical Trial Update: Sequentiality of Everolimus and STZ-5FU in Advanced Pancreatic Neuroendocrine Tumor [Phase 3]
Phase 3 trial evaluating sequential therapy with Everolimus followed by STZ-5FU in advanced pancreatic neuroendocrine tumors has completed a…
-
CLINICAL_TRIALS trial_result · 2025-05-06Clinical Trial Update: Role of Proton Pump Inhibitors on the Postoperative Course Following Pancreaticoduodenectomy [Phase 2]
Phase 2 trial evaluating the effect of proton pump inhibitors on postoperative recovery after pancreaticoduodenectomy; the study was termina…
-
CLINICAL_TRIALS research · 2025-05-02Clinical Trial Update: Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver [EARLY_Phase 1]
This clinical trial update describes an early-phase study of Lutathera in people with gastroenteropancreatic, bronchial, or unknown primary …
-
CLINICAL_TRIALS research · 2025-05-02Clinical Trial Update: Iconographic Registry of Pancreatobiliary Endoscopy Procedures
This is a clinical trial registry entry for an endoscopy study in pancreatic diseases that is currently recruiting, listing pancreatic cance…
-
CLINICAL_TRIALS research · 2025-05-01Clinical Trial Update: Development of New Personalised 3D Preclinical Models of Pancreatic Neuroendocrine Tumours
This entry reports on a clinical trial aimed at developing personalised 3D preclinical models for pancreatic neuroendocrine tumors. The stud…
-
CLINICAL_TRIALS trial_result · 2025-04-20Clinical Trial Update: Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II [Phase 2]
This document reports the completion of a randomized Phase II trial comparing peptide receptor radionuclide therapy with Lutetium-177 dotata…
-
CLINICAL_TRIALS research · 2025-04-02Clinical Trial Update: Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors [Phase 2]
Phase 2 clinical trial evaluating a capecitabine-temozolomide combination versus Lutetium-177 dotatate in patients with advanced pancreatic …
-
FDA approval · 2025-02-14FDA Approved: SUNITINIB MALATE — Original Application (Novadoz Pharmaceuticals LLC)
The FDA approved an original generic application for sunitinib malate from Novadoz Pharmaceuticals LLC. This approval provides a generic opt…